

ERRATUM

Open Access



Erratum to: Looking forward to new targeted treatments for chronic spontaneous urticaria

Emek Kocatürk^{1*} , Marcus Maurer², Martin Metz² and Clive Grattan³

Erratum to: *Clin Transl Allergy* (2017) 7:1 DOI 10.1186/s13601-016-0139-2

Information from the manufacturer of the topical intervention in the GSK2646264 trial outlined in this review [1] indicates that the half-life of the product has not been established with certainty on the available data.

Author details

¹ Department of Dermatology, Okmeydanı Training and Research Hospital, Istanbul, Turkey. ² Department of Dermatology and Allergy, Charité – Universitätsmedizin, Berlin, Germany. ³ St John's Institute of Dermatology, Guy's Hospital, London, UK.

The online version of the original article can be found under doi:10.1186/s13601-016-0139-2.

Received: 13 March 2017 Accepted: 13 March 2017
Published online: 03 April 2017

Reference

1. Kocatürk E, Maurer M, Metz M, Grattan C. Looking forward to new targeted treatments for chronic spontaneous urticaria. *Clin Transl Allergy*. 2017;7:1.

*Correspondence: dremekozgur@gmail.com

¹ Department of Dermatology, Okmeydanı Training and Research Hospital, Istanbul, Turkey
Full list of author information is available at the end of the article